PD173074

Licensed by Pfizer Catalog No.S1264

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Size Price Stock Quantity  
In DMSO USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331(6019), 912-6. PD173074 purchased from Selleck.

    Inhibition of FGFR signaling pathway by FGFR inhibitor PD173074 in mouse xenograft tumors. Bladder cancer SW780 cells were implanted in mice and treated with PD173074 after tumor formation as shown in B. Protein lysates of tumor tissues were prepared and immunoblotted with antibodies against phospho-ERK1/2, pan-ERK1/2, and γ-tubulin.

    Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck.

  • FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.

    Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck.

    The level of p-FRS2 was examined in the uterine sections of Msx1f/fMsx2f/f (upper panel) and Msx1d/dMsx2d/d (lower panel) mice on day 4 of pregnancy by immunohistochemistry. Magnification: a and d: 10 x, b and e: 20 x, c and f: 40x. FGFR-specific inhibitor PD173074 was applied to one uterine horn of Msx1d/dMsx2d/d (n = 3) mice on day 3 of pregnancy. The other horn served as vehicle-treated control. Uterine horns were collected on day 4 morning and sections were subjected to immunohistochemistry to detect p-FRS2, Ki67, and Muc-1.

    PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck.

  • Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 ℃ for 48 h, and the appearance of the mature protein, band C, monitored by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle- alone control, 27℃ represents temperature rescue of F508-CFTR at 27℃, 37℃ represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.

    Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck.

    Cells were incubated with DMSO control, 10 uM TGFBR inhibitor or 10 uM FGFR inhibitor PD173074 for 1 h. Cells were fixed, labeled with anti-GM130 (red) and analyzed by confocal microscopy. Images were analyzed using Image J (n = 3 experiments, >100 cells per condition). Scale bars, 10 uM.

    J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck.

  • Effects of antagonists for RAGE (FPS-ZM), TLR-4 (TAK-242) and FGFR1 (PD and BGJ) on the S100B-induced alterations in glucose metabolism in L6 cells treated for 6 h. (A) Effects of FPS-ZM, (B) TAK-242 and (C) PD and BGJ on the S100B inhibition of glucose consumption.

    Am J Physiol Endocrinol Metab, 2017, 312(6):E471-E481. PD173074 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEGyNlUh|ryP NUfXPXFpW0GQR1XS
KG-1 M{H6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPmTG1PUUN3ME2wMlA2OTJ7IN88US=> M1jqPHNCVkeHUh?=
MFM-223 NEPE[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vmV2lEPTB;MD6yNVU4PiEQvF2= NGLZWGxUSU6JRWK=
EoL-1-cell NV3KV251T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnkTWM2OD1yLkOyPVg1KM7:TR?= MXPTRW5ITVJ?
ECC10 M{PHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDkTmtKSzVyPUCuN|M5QThizszN MVfTRW5ITVJ?
H-EMC-SS NWPKe5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrIdVBVUUN3ME2wMlM1PzF3IN88US=> NVrYOIZbW0GQR1XS
AN3-CA MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPNfoFNUUN3ME2wMlQxOTN|IN88US=> MkHOV2FPT0WU
HuO-3N1 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jKdmlEPTB;MD61OFY2OyEQvF2= NV75[Zh7W0GQR1XS
RT-112 NYrjcoVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL0dVRKSzVyPUCuOVQ4ODFizszN MYLTRW5ITVJ?
NEC8 M2fCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\MeJJKSzVyPUCuOVYzQDlizszN MXjTRW5ITVJ?
D-263MG M2rNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP6So5xUUN3ME2wMlcyOTV7IN88US=> MWXTRW5ITVJ?
SW962 NGDs[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvSTFJKSzVyPUCuO|g6QDhizszN NX7qd3h2W0GQR1XS
BV-173 NWe4ZZkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWK1cm1TUUN3ME2wMlg1PjJ|IN88US=> MkKyV2FPT0WU
MFE-280 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz4TWNSUUN3ME2wMlg2QDd{IN88US=> M1;TPHNCVkeHUh?=
HuH-7 NWXi[WZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwMkS0OlQh|ryP M4jnRnNCVkeHUh?=
RS4-11 NXv6XmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwM{O4PFYh|ryP MVfTRW5ITVJ?
DMS-114 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XOXWlEPTB;MT6zOlc{PyEQvF2= NHjZVodUSU6JRWK=
MSTO-211H NVTLXJhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7GdYpmUUN3ME2xMlQ4Ozd6IN88US=> MYXTRW5ITVJ?
DU-145 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzhdWRKSzVyPUGuOVgzOTdizszN Mm\6V2FPT0WU
A172 M4jlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi5eotDUUN3ME2xMlcxOzV3IN88US=> MnLVV2FPT0WU
SBC-1 M3P4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrkTWM2OD1{LkC5OEDPxE1? MYTTRW5ITVJ?
H9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:xSmlEPTB;Mj6xOFMxPiEQvF2= NFvuZW5USU6JRWK=
NCI-SNU-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDS[GVwUUN3ME2yMlE5Ozl2IN88US=> NE\MbWxUSU6JRWK=
NCI-H720 NIrIToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwMkGyPFMh|ryP MWTTRW5ITVJ?
HCC2218 M{W4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOxS4lKSzVyPUKuN|c6OzlizszN MUPTRW5ITVJ?
G-401 NH;uZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwNEexPFkh|ryP M17qdnNCVkeHUh?=
MPP-89 NVrTdYw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknSTWM2OD1{LkS4N|Y1KM7:TR?= M3jXbXNCVkeHUh?=
697 M{n2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITYflZKSzVyPUKuOlU{OzFizszN M2fxO3NCVkeHUh?=
KARPAS-45 NWLLZpRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu3U3hKSzVyPUKuO|A4PDdizszN MWfTRW5ITVJ?
MG-63 NWe5d3d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7QTWM2OD1{Lkm0NlYzKM7:TR?= MYDTRW5ITVJ?
NTERA-S-cl-D1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLCVnhzUUN3ME2zMlA{PDd{IN88US=> NVrIe4JvW0GQR1XS
G-402 NUfzSG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G4NWlEPTB;Mz6xNlczPyEQvF2= M3m5c3NCVkeHUh?=
NKM-1 NFPxdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfjWpJKSzVyPUOuNVM2PjRizszN NWDySGxRW0GQR1XS
RH-18 NETxTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHXdJpGUUN3ME2zMlE6PTl6IN88US=> Mn\KV2FPT0WU
NCI-H1092 M4XieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKyTWM2OD1|LkG5Olkh|ryP NIDp[4RUSU6JRWK=
RPMI-8226 NFO4cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1njb2lEPTB;Mz6yN|Q1PyEQvF2= NYe0cox3W0GQR1XS
GAMG M4HiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO5b3hKSzVyPUOuOFY2PzZizszN M3[xRXNCVkeHUh?=
HH M3LFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLHR4plUUN3ME2zMlQ4Pjd4IN88US=> MVHTRW5ITVJ?
RO82-W-1 NH;NZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3sTWM2OD1|LkS5PFU2KM7:TR?= NYnwblcxW0GQR1XS
CCRF-CEM MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPaS4xKSzVyPUOuOVA1QDhizszN NGjYOo9USU6JRWK=
NBsusSR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\oe45KSzVyPUOuOlM6PjlizszN MnX4V2FPT0WU
CHL-1 M3vlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r5TWlEPTB;Mz62OVc6QSEQvF2= NHXiVFRUSU6JRWK=
LK-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwNkexN|Mh|ryP NVexWXFLW0GQR1XS
Hs-578-T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHtdm1KSzVyPUOuOlc5PzNizszN MnrCV2FPT0WU
CTB-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwOECwOVEh|ryP NGDpeZpUSU6JRWK=
ES5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTNwOEO2N|ch|ryP MoT6V2FPT0WU
A204 M{Loemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrOS45KSzVyPUOuPVIxPzVizszN NFLnb3BUSU6JRWK=
SW780 MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG5TWM2OD1|LkmyNlQ2KM7:TR?= MYTTRW5ITVJ?
EW-3 NFPnNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MontTWM2OD1|Lkm4PVI{KM7:TR?= NULvb5dQW0GQR1XS
A704 NXPueppbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLmbmNKSzVyPUSuNlg4OjNizszN MX\TRW5ITVJ?
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[5ZnJKSzVyPUSuN|E2OzRizszN M4PQRXNCVkeHUh?=
CAL-72 M4\IeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnsfWpKSzVyPUSuOFE4PDZizszN NWHHTXN[W0GQR1XS
D-336MG NUWyZYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K0[GlEPTB;ND60OlgyPyEQvF2= MmHXV2FPT0WU
LAMA-84 NYH3R|R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHkS4lNUUN3ME20MlU{OzFizszN MkT3V2FPT0WU
GI-ME-N NXjxR2VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7GRWtKSzVyPUSuOVQ5OSEQvF2= MkTEV2FPT0WU
KM-H2 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7k[FRHUUN3ME20MlU2OjJ{IN88US=> MYDTRW5ITVJ?
NCI-H209 M3LuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M134RWlEPTB;ND61PFI5OyEQvF2= MW\TRW5ITVJ?
IGROV-1 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki2TWM2OD12Lki3NVY5KM7:TR?= NG[wPIZUSU6JRWK=
L-363 NIXzc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nxcGlEPTB;ND65OlY3PSEQvF2= MoDZV2FPT0WU
SK-MEL-3 NWDKNVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW5PW5IUUN3ME21MlI1ODZizszN MofJV2FPT0WU
HuO9 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwM{i4OFMh|ryP MmfpV2FPT0WU
NOS-1 NUXtUW9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW0TWM2OD13LkeyPVI4KM7:TR?= NXf5UVE6W0GQR1XS
NCI-H1770 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm4WFQ5UUN3ME21Mlk2ODN{IN88US=> NVjBbJVCW0GQR1XS
SF126 NUPxUG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILYPXNKSzVyPU[uNlE1ODZizszN MlXtV2FPT0WU
ML-2 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pdo1pUUN3ME22MlI1QTd5IN88US=> NGDESo5USU6JRWK=
CHP-134 NXnkc3dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npUGlEPTB;Nj6yOVE5OiEQvF2= MYnTRW5ITVJ?
NCI-H1355 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnwd4FKSzVyPU[uOFE4OzNizszN NWrFW3AzW0GQR1XS
TE-12 NYrDb3k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTZwN{K2O|Eh|ryP MV;TRW5ITVJ?
A4-Fuk MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1OGlEPTB;Nj63N|E1OiEQvF2= NUXVRphJW0GQR1XS
MV-4-11 MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\CS49uUUN3ME22Mlc3PjJ4IN88US=> NYK1NIhuW0GQR1XS
SK-UT-1 M{HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnCTWM2OD14LkmxO|g1KM7:TR?= NF\oRWdUSU6JRWK=
J-RT3-T3-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TR[GlEPTB;Nz6wO|c3PCEQvF2= Ml7JV2FPT0WU
ME-180 NYHDSWdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfRUpNKSzVyPUeuNVA1ODRizszN NITlendUSU6JRWK=
SK-MEL-28 NWT4coFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zDbWlEPTB;Nz6zO|gyQSEQvF2= NV;DVGIxW0GQR1XS
HAL-01 NY\rcZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\R[2dEUUN3ME23MlQ5OzRzIN88US=> NHrGUIpUSU6JRWK=
ES8 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT1TWM2OD15Lk[5OlI3KM7:TR?= Mn21V2FPT0WU
DB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvQSWxKSzVyPUiuNVE2ODRizszN NYrmSHh5W0GQR1XS
SK-NEP-1 NEPEOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWzZVNWUUN3ME24MlQ5OTR7IN88US=> M1fPTHNCVkeHUh?=
COR-L88 NHnMcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRThwNUC5PFEh|ryP M{PJcXNCVkeHUh?=
LB1047-RCC NFjN[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRThwNUKyNVIh|ryP MlfmV2FPT0WU
NCI-H520 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jpS2lEPTB;OD62NlE2PyEQvF2= NXnrWXA2W0GQR1XS
SW954 NI\WZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nOW2lEPTB;OD62PVc5PiEQvF2= MVHTRW5ITVJ?
TE-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfqTWM2OD16Lke1NVQ{KM7:TR?= NEjscJFUSU6JRWK=
D-283MED NYrvPZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEniNoVKSzVyPUmuNFY2OzRizszN NUDZXWU1W0GQR1XS
DBTRG-05MG NWC1NVBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH73fVdKSzVyPUmuNFk3ODdizszN MX\TRW5ITVJ?
NCI-H446 NV\kfZM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XtVGlEPTB;OT6yPVUzPiEQvF2= NYHsWphNW0GQR1XS
HOS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPMTWM2OD17LkO1NVM1KM7:TR?= M4X1ZnNCVkeHUh?=
ES4 NEnKO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2juXmlEPTB;OT61NFU6PSEQvF2= NWXEbYF1W0GQR1XS
EW-13 NEe2OmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTlwOEmwOVUh|ryP M32y[nNCVkeHUh?=
IST-MES1 NF[0UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NXWlEPTB;OT65OFU{PCEQvF2= M3PGN3NCVkeHUh?=
CAS-1 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTlwOUe2OVkh|ryP NYHKeIRLW0GQR1XS
EM-2 MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfTSJJVUUN3ME2xNE4yOzl|IN88US=> NW\2SWlIW0GQR1XS
SW948 M333dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jORWlEPTB;MUCuNVg5OiEQvF2= NGnZTZRUSU6JRWK=
OAW-42 M{XwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG0N2dKSzVyPUGwMlUzPjdizszN NFXyTHRUSU6JRWK=
BE-13 NFywXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFyLk[1O|Yh|ryP Mn\0V2FPT0WU
KU812 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGwTWM2OD1zMD63N|kyKM7:TR?= M4K0[3NCVkeHUh?=
SK-MEL-30 NWLa[2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLmTWM2OD1zMD64PVAyKM7:TR?= M3W0THNCVkeHUh?=
A2780 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLrPJVUUUN3ME2xNU4xOzB6IN88US=> MVXTRW5ITVJ?
TGBC24TKB M1;mdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfyPI9HUUN3ME2xNU4xPzN5IN88US=> MoPJV2FPT0WU
GOTO NYntO4Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvUeZRKSzVyPUGxMlIxQDRizszN MVHTRW5ITVJ?
NCI-H526 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXoeY1HUUN3ME2xNU4{QDN5IN88US=> MUnTRW5ITVJ?
BHT-101 NXHpVm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;3RWFKSzVyPUGxMlQ1PTZizszN M1vmVXNCVkeHUh?=
NCI-H1155 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KzdWlEPTB;MUGuOFk1PyEQvF2= NEGyVXFUSU6JRWK=
MCF7 NH7qTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV62emoxUUN3ME2xNU43OTZ5IN88US=> MmjVV2FPT0WU
MKN45 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;PeFMxUUN3ME2xNU44QTl|IN88US=> NFTWemZUSU6JRWK=
MOLT-16 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTITWM2OD1zMT65OlkzKM7:TR?= MX\TRW5ITVJ?
YH-13 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLBTWM2OD1zMj6wN|Q3KM7:TR?= MVzTRW5ITVJ?
P12-ICHIKAWA NVHCe|BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTNTWM2OD1zMj6zPFQ2KM7:TR?= NITSUINUSU6JRWK=
GR-ST M2nD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXUN3hKSzVyPUGyMlUzQTVizszN MlfIV2FPT0WU
CAKI-1 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\XNWlEPTB;MUKuO|kyKM7:TR?= NUXtPJZnW0GQR1XS
LXF-289 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF|LkC4N|Uh|ryP M{L3WHNCVkeHUh?=
MHH-PREB-1 M3TTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF|LkK3NFQh|ryP MV3TRW5ITVJ?
EW-16 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF|LkOxPFch|ryP M2nTXXNCVkeHUh?=
NCI-H82 NGPtV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;zVVVpUUN3ME2xN{41OTl3IN88US=> NFzXcXFUSU6JRWK=
MMAC-SF NYSxN5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHoUmF6UUN3ME2xN{41PTR5IN88US=> NH\EdpBUSU6JRWK=
COLO-684 NXq0emRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG5fFVKSzVyPUGzMlU{OThizszN NWDXcWFzW0GQR1XS
QIMR-WIL NEXDc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLHTWM2OD1zMz64NVA6KM7:TR?= MWXTRW5ITVJ?
NB69 NGjRR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF|Lkm4Olgh|ryP MUTTRW5ITVJ?
NCI-H2291 NV\iWZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2LkS0OVMh|ryP MXLTRW5ITVJ?
MKN7 NWDwb3J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHzN4hVUUN3ME2xOE43Pjd4IN88US=> NW\mWnByW0GQR1XS
HDLM-2 M2X6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jyO2lEPTB;MUWuNVI5PiEQvF2= NWrreo5jW0GQR1XS
A253 Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLMTWM2OD1zNT6zPFY6KM7:TR?= M36zVnNCVkeHUh?=
SK-LU-1 M2rYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoftTWM2OD1zNT65NFk1KM7:TR?= NVTxUlVyW0GQR1XS
MEG-01 M{LSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3udoFKSzVyPUG1MlkyODdizszN MmPjV2FPT0WU
SK-N-DZ NXqyb5BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrZWtXUUN3ME2xOU46Ozd4IN88US=> MWXTRW5ITVJ?
H4 NG\XXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXJfopXUUN3ME2xOk4xQDhizszN M1fI[XNCVkeHUh?=
LU-65 M3TqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorMTWM2OD1zNj6zN|g1KM7:TR?= MljFV2FPT0WU
NCI-H1048 NHfLb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKzbo1KSzVyPUG2MlUyPjVizszN M{nKR3NCVkeHUh?=
LCLC-97TM1 NHjSfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzDVo1KSzVyPUG2MlU5QDlizszN M3fj[nNCVkeHUh?=
CAL-120 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfENFFpUUN3ME2xOk46QDd7IN88US=> MVXTRW5ITVJ?
LU-134-A MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\jcFFMUUN3ME2xO{4{OzlzIN88US=> M37ES3NCVkeHUh?=
SK-MEL-1 NYjnXFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF5LkexNlch|ryP NYPzRlBlW0GQR1XS
NCI-H69 NWLxUWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF5LkmzNFch|ryP MY\TRW5ITVJ?
MC116 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HTbGlEPTB;MUeuPVc2KM7:TR?= MWrTRW5ITVJ?
UMC-11 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPFRmJKSzVyPUG4MlE4QDhizszN NVPjWm1[W0GQR1XS
HCC1395 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjiTItrUUN3ME2xPE41OzBzIN88US=> MXPTRW5ITVJ?
no-10 NGfLRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF6Lk[zPFgh|ryP NU\hOlI1W0GQR1XS
NY NUn6enBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF7LkC4NFkh|ryP M1jLR3NCVkeHUh?=
OS-RC-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\2T2lEPTB;MUmuNVI2OiEQvF2= MkHuV2FPT0WU
D-423MG M3z0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInNS5dKSzVyPUG5MlM6PTJizszN NY\QUYxSW0GQR1XS
LC-2-ad MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLoSIxjUUN3ME2xPU44PjF{IN88US=> M1HUe3NCVkeHUh?=
DU-4475 NXv5WW9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrOTWM2OD1zOT64PFUzKM7:TR?= M1XDc3NCVkeHUh?=
YKG-1 NGniWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILYbmFKSzVyPUG5Mlk3OiEQvF2= M3XJRnNCVkeHUh?=
HCC1569 M{XNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonzTWM2OD1{MD6yOlI1KM7:TR?= M2r6O3NCVkeHUh?=
TYK-nu NXjUbJpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvGNXVIUUN3ME2yNE4zQDR5IN88US=> NVvOXGpiW0GQR1XS
DEL MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TPc2lEPTB;MkCuPVgxQCEQvF2= M2jsO3NCVkeHUh?=
MHH-ES-1 NUGyc3FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XPfGlEPTB;MkGuN|U6PyEQvF2= MYLTRW5ITVJ?
KARPAS-299 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXWO3VVUUN3ME2yNU42OjlizszN NGfSd|dUSU6JRWK=
CTV-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G2eGlEPTB;MkGuOlE4OiEQvF2= M1\ZfHNCVkeHUh?=
NCI-H2452 NVP6d29GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fmbWlEPTB;MkKuOlY4PyEQvF2= M{XRSnNCVkeHUh?=
D-566MG NH7tUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7rVIdOUUN3ME2yNk44PjBzIN88US=> M4jvd3NCVkeHUh?=
EFO-27 M4XOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C2UWlEPTB;MkOuNFY2OSEQvF2= Ml3xV2FPT0WU
NCI-H596 NF;ISFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrKblRKSzVyPUKzMlg2OjdizszN MmHXV2FPT0WU
KS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHrOGRiUUN3ME2yOE4zPzV7IN88US=> NHLRWI5USU6JRWK=
8305C MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TK[mlEPTB;MkSuOFA1PSEQvF2= NWrZe3NGW0GQR1XS
A427 NY\mPGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ3LkCzNlMh|ryP M1f1S3NCVkeHUh?=
COLO-800 NEXoc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e0NWlEPTB;MkWuNVA3OSEQvF2= M1rVZXNCVkeHUh?=
SJRH30 NXr5RZZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHxTWM2OD1{NT6zPVA5KM7:TR?= MkfpV2FPT0WU
MEL-HO NUXCOXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ3LkSzNVkh|ryP NY\TT5BoW0GQR1XS
FTC-133 NWnqb|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPO[W5IUUN3ME2yOU45OTh4IN88US=> MknTV2FPT0WU
SF295 NFPoWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ4LkK5OkDPxE1? MYrTRW5ITVJ?
SW1710 NI\3TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LY[GlEPTB;Mk[uOFEzOyEQvF2= MkXUV2FPT0WU
EFM-19 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ4LkixOFUh|ryP MnH3V2FPT0WU
NB10 NVu0WnJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnnblA6UUN3ME2yPE4zOjl5IN88US=> MlS4V2FPT0WU
TK10 NWm0blFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ6LkKzPVkh|ryP M{juWHNCVkeHUh?=
D-502MG M{fVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonmTWM2OD1{OD60JO69VQ>? M1HtPXNCVkeHUh?=
EW-18 NWDWb21qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ6LkSzPFYh|ryP MkL5V2FPT0WU
VMRC-RCZ NXnJRlV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ6Lkm0NUDPxE1? MYLTRW5ITVJ?
Ca9-22 M2fISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG4TWM2OD1{OT60OVU4KM7:TR?= MYXTRW5ITVJ?
KYSE-70 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ7LkW3PFYh|ryP NEDEZ2xUSU6JRWK=
A101D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HtZ2lEPTB;MkmuOlQ4OiEQvF2= MUXTRW5ITVJ?
WM-115 NXjYS4hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[5TWM2OD1{OT63OlA4KM7:TR?= NX33OmlbW0GQR1XS
HCC2157 M2jaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ7Lki4NFch|ryP MUPTRW5ITVJ?
TE-9 NEDxRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnyeJdjUUN3ME2yPU45QDZ3IN88US=> M3:2V3NCVkeHUh?=
K-562 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHryU3NKSzVyPUOwMlA6OzNizszN NYDufo5NW0GQR1XS
SN12C NVf0[FN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHGZnVKSzVyPUOwMlE1OjZizszN MYPTRW5ITVJ?
ESS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXSTWM2OD1|MD60O|U6KM7:TR?= MYLTRW5ITVJ?
K5 M2\Bbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHKeJZKSzVyPUOwMlc3PCEQvF2= Mn3UV2FPT0WU
J82 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HvWWlEPTB;M{GuNFg6PyEQvF2= MoXjV2FPT0WU
HOP-92 NUn6WXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC4WWlKSzVyPUOxMlEyOTFizszN M{m1cXNCVkeHUh?=
NCI-H2228 M3jyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvO[llpUUN3ME2zNU4{Ojl4IN88US=> M37FVHNCVkeHUh?=
OCI-AML2 NIXYdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HkO2lEPTB;M{GuN|YyKM7:TR?= MkW3V2FPT0WU
NCI-SNU-5 M2XtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\QTWM2OD1|MT64NVM4KM7:TR?= MUTTRW5ITVJ?
A3-KAW NX\1[nVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rsTmlEPTB;M{GuPVI1OyEQvF2= M1XrenNCVkeHUh?=
LCLC-103H Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX4TWM2OD1|Mj6wNVcyKM7:TR?= MYPTRW5ITVJ?
KY821 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q1eWlEPTB;M{KuOlg5PCEQvF2= MnvRV2FPT0WU
JVM-2 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN{LkmwO|kh|ryP MoLNV2FPT0WU
Mo-T NFrBS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN|LkGwNFUh|ryP NHP4W5VUSU6JRWK=
IA-LM NYfZcFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\xfIRuUUN3ME2zN{4zPzVizszN NHfPRY1USU6JRWK=
C8166 M{GydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN|LkOxPVIh|ryP MVPTRW5ITVJ?
TCCSUP NH3YWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN|LkSzNFch|ryP MoGyV2FPT0WU
JEG-3 MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\BfGlEPTB;M{OuOFc3QCEQvF2= MmT4V2FPT0WU
MS-1 M1fybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33C[WlEPTB;M{OuOVU2OSEQvF2= M3vycHNCVkeHUh?=
NCI-H1304 NVz0S5YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN|LkW3NlUh|ryP NGTRNolUSU6JRWK=
Ramos-2G6-4C10 NGXiU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PCXWlEPTB;M{SuNFM{PSEQvF2= M2DDSHNCVkeHUh?=
MDA-MB-453 M2OyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN2Lk[zPVUh|ryP M1nvVnNCVkeHUh?=
KYSE-520 M1zGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqzfYtKSzVyPUO0MlcyQDFizszN MY\TRW5ITVJ?
SW900 Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jCe2lEPTB;M{SuPFEyPSEQvF2= NXHTdosyW0GQR1XS
HCC2998 M2LUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPqRpJKSzVyPUO1MlE2OjlizszN MYXTRW5ITVJ?
A2058 NEfWN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;YemlEPTB;M{WuOlA3OSEQvF2= NFz6SlFUSU6JRWK=
OVCAR-3 NGqzN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4cXRKSzVyPUO2MlIxPDVizszN NIrQ[lRUSU6JRWK=
MOLT-4 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTN4LkKyPVQh|ryP MX7TRW5ITVJ?
CAPAN-1 M3fzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN4LkS2PVkh|ryP NYeydnVpW0GQR1XS
SCC-9 NXTOfmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fDTGlEPTB;M{euOFAzPyEQvF2= NH\TV5dUSU6JRWK=
SF268 NXfHXnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnraTWM2OD1|OD6zOFM{KM7:TR?= MUPTRW5ITVJ?
HGC-27 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e4O2lEPTB;M{iuN|cyOSEQvF2= NFHIfpFUSU6JRWK=
DOHH-2 NVu3OYd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLrUZBKSzVyPUO4MlcyPThizszN MXPTRW5ITVJ?
KE-37 M1XlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN6Lkm4Nlgh|ryP MYfTRW5ITVJ?
MOLT-13 M3nuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjlWVRKSzVyPUO5MlI2ODJizszN Mn7kV2FPT0WU
ES1 NXL6WVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW4[2FKSzVyPUO5MlM5PSEQvF2= NW[x[GlDW0GQR1XS
SK-OV-3 NVy4dYZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN7Lkm2OFMh|ryP NIH1dIhUSU6JRWK=
SNU-449 NET2S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf4eItKSzVyPUSwMlA4PjRizszN MX\TRW5ITVJ?
KYSE-510 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLvVYp[UUN3ME20NE4yOjl3IN88US=> MXXTRW5ITVJ?
HL-60 M1vLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[5TWM2OD12MD65O|g{KM7:TR?= NFXiTFRUSU6JRWK=
DJM-1 NF3VZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTQ[mJRUUN3ME20NE46Pzl7IN88US=> M3L1N3NCVkeHUh?=
TGBC11TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\aTWRKSzVyPUSxMlA6OjZizszN MULTRW5ITVJ?
U-2-OS MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XYcGlEPTB;NEKuNlY1OSEQvF2= M3OzSHNCVkeHUh?=
NCI-H2030 NHL2U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljxTWM2OD12Mj60N|Y5KM7:TR?= NYjmOVdYW0GQR1XS
LU-135 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR{LkW0OFch|ryP MUjTRW5ITVJ?
ZR-75-30 NFLUTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDFV41JUUN3ME20N{4xPDl|IN88US=> M1;JWHNCVkeHUh?=
GT3TKB MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW5TWM2OD12Mz6yOlc6KM7:TR?= NFnV[3NUSU6JRWK=
RPMI-2650 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewfmlEPTB;NEOuO|gyPiEQvF2= MonDV2FPT0WU
SAS Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiyTWM2OD12Mz65OVM1KM7:TR?= NHHXbYdUSU6JRWK=
MDA-MB-231 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTR|Lkm2NFkh|ryP M1zCenNCVkeHUh?=
JVM-3 NW\pU5ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LldGlEPTB;NESuNFU{OyEQvF2= NWi0TJRRW0GQR1XS
COLO-320-HSR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nIOGlEPTB;NESuOVY{OyEQvF2= NWfDSnN{W0GQR1XS
SNB75 NHTWSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR2Lk[xNFUh|ryP NFnuR3FUSU6JRWK=
NCI-H441 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\YOHBKSzVyPUS0Mlk{OjhizszN Ml20V2FPT0WU
HCT-116 M3;iSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme0TWM2OD12ND65PFY5KM7:TR?= MYTTRW5ITVJ?
NCI-H226 M3H3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmzclFSUUN3ME20OU43OzZ6IN88US=> NGXhT5NUSU6JRWK=
CAL-33 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK2TWM2OD12NT65NlE4KM7:TR?= NFvaPXFUSU6JRWK=
NCI-H1437 NWHZcFE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrDS4dKSzVyPUS2MlMzOSEQvF2= M3\sNXNCVkeHUh?=
HCC1187 M{f6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzLTWM2OD12Nj60NlU2KM7:TR?= MVHTRW5ITVJ?
NUGC-3 NUK4cWF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR4LkW3NFkh|ryP NVr3XnRxW0GQR1XS
T98G MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTR5LkW0O{DPxE1? M2XtbXNCVkeHUh?=
OVCAR-8 NFrPbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn1fmpTUUN3ME20O{43QDNizszN MkHrV2FPT0WU
LB2241-RCC NXuybYJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDLTWM2OD12Nz63Nlch|ryP MVnTRW5ITVJ?
NCI-H358 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7xTWM2OD12OD6xNVUzKM7:TR?= NIXGdVZUSU6JRWK=
PANC-08-13 NFjtSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2NGlEPTB;NEiuNVg2OyEQvF2= MmPTV2FPT0WU
KP-N-YN NYDyW5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfPOmZKSzVyPUS4MlIyODJizszN MoryV2FPT0WU
NCI-H1755 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXziZ5RKUUN3ME20PE4zPzJ4IN88US=> Mmq2V2FPT0WU
NCI-N87 M13tWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXhSm1IUUN3ME20PE4zQTlzIN88US=> MmnqV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
+ Expand
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Formulation: Prepared in sterile fashion
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID